Literature DB >> 20636166

Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care.

Scott A Irwin1, Alana Iglewicz.   

Abstract

Depression is prevalent and undertreated in patients receiving hospice care. Standard antidepressants do not work rapidly or often enough to benefit most of these patients. Here, two cases are reported in which a single oral dose of ketamine provided rapid and moderately sustained symptom relief for both depression and anxiety. In addition, no adverse effects were noted. Further investigation with randomized, controlled clinical trials is necessary to firmly establish the effectiveness of oral ketamine for the treatment of depression and anxiety in patients receiving hospice care. Ketamine may be a promising safe, effective, and cost-effective rapid treatment for depression and anxiety in this population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20636166      PMCID: PMC3120058          DOI: 10.1089/jpm.2010.9808

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  27 in total

1.  Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.

Authors:  P G Fine
Journal:  J Pain Symptom Manage       Date:  1999-04       Impact factor: 3.612

2.  Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine.

Authors:  Edward J Fitzgibbon; Pippa Hall; Cori Schroder; John Seely; Raymond Viola
Journal:  J Pain Symptom Manage       Date:  2002-02       Impact factor: 3.612

3.  A survey of psychotropic use in terminal cancer patients.

Authors:  R J Goldberg; V Mor
Journal:  Psychosomatics       Date:  1985-09       Impact factor: 2.386

4.  Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.

Authors:  G R Lauretti; I C Lima; M P Reis; W A Prado; N L Pereira
Journal:  Anesthesiology       Date:  1999-06       Impact factor: 7.892

5.  Successful use of ketamine for intractable cancer pain.

Authors:  Dominique A Lossignol; Myriam Obiols-Portis; Jean-Jacques Body
Journal:  Support Care Cancer       Date:  2004-10-06       Impact factor: 3.603

6.  Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient.

Authors:  J L Clark; G E Kalan
Journal:  J Pain Symptom Manage       Date:  1995-05       Impact factor: 3.612

Review 7.  Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review.

Authors:  Kathirvel Subramaniam; Balachundhar Subramaniam; Richard A Steinbrook
Journal:  Anesth Analg       Date:  2004-08       Impact factor: 5.108

Review 8.  National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002.

Authors:  Daniel L Patrick; Sandra L Ferketich; Paul S Frame; Jesse J Harris; Carolyn B Hendricks; Bernard Levin; Michael P Link; Craig Lustig; Joseph McLaughlin; L Douglas Reid; Andrew T Turrisi; Jürgen Unützer; Sally W Vernon
Journal:  J Natl Cancer Inst Monogr       Date:  2004

9.  Group therapy and hypnosis reduce metastatic breast carcinoma pain.

Authors:  D Spiegel; J R Bloom
Journal:  Psychosom Med       Date:  1983-08       Impact factor: 4.312

10.  Small-dose ketamine improves the postoperative state of depressed patients.

Authors:  Akira Kudoh; Yoko Takahira; Hiroshi Katagai; Tomoko Takazawa
Journal:  Anesth Analg       Date:  2002-07       Impact factor: 5.108

View more
  36 in total

1.  CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Authors:  Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 2.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 3.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

4.  Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.

Authors:  Scott A Irwin; Alana Iglewicz; Richard A Nelesen; Jessica Y Lo; Connie H Carr; Sheilani D Romero; Linda S Lloyd
Journal:  J Palliat Med       Date:  2013-06-27       Impact factor: 2.947

5.  The Epidemiology of Depressive Symptoms in the Last Year of Life.

Authors:  Elissa Kozlov; XinQi Dong; Amy S Kelley; Claire K Ankuda
Journal:  J Am Geriatr Soc       Date:  2019-11-05       Impact factor: 5.562

6.  New use for an old drug: oral ketamine for treatment-resistant depression.

Authors:  Kevin M Swiatek; Kim Jordan; Julie Coffman
Journal:  BMJ Case Rep       Date:  2016-08-03

Review 7.  Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population.

Authors:  Charlene Faye; Josephine C Mcgowan; Christine A Denny; Denis J David
Journal:  Curr Neuropharmacol       Date:  2018-03-05       Impact factor: 7.363

Review 8.  Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.

Authors:  Faryal Mallick; Cheryl B McCullumsmith
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

9.  The effects of brain serotonin deficiency on behavioural disinhibition and anxiety-like behaviour following mild early life stress.

Authors:  Benjamin D Sachs; Ramona M Rodriguiz; William B Siesser; Alexander Kenan; Elizabeth L Royer; Jacob P R Jacobsen; William C Wetsel; Marc G Caron
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

Review 10.  [Drug therapy of anxiety and fear in palliative care patients with cancer or other illnesses : a systematic review].

Authors:  G Nübling; S Allmendinger; S Lorenzl
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.